Clinical trials: Radiation-induced Lung Injury
Non-small Cell Lung Cancer, Radiation Toxicity
Radiation-induced Cardiac Toxicity After Non-small Cell Lung Cancer Radiotherapy
Despite the growing interest in investigating how the radiotherapy (RT) dose to anatomical substructures of the heart links to survival, the heart substructures at risk remain poorly defined.
- Conditions
- Non-small Cell Lung Cancer, Radiation Toxicity, Cardiac Toxicity
- Trial name
- NCT04867564
- Testing
- Echocardiography
- Where
- Poland
- Volunteers
- 100 people
- Sponsor
- Military Institute od Medicine National Research Institute
Cardiac Disease, Covid19
Validation of Quantitative Myocardial Tissue Characterization Through Non-gated CT
The main aim is to validate non-gated 5-min computed tomography myocardial relative enhancement (CT-MRE), which can be readily estimated via contrast-enhanced non-gated chest CT, as a tool for estimating myocardial extracellular…
- Conditions
- Cardiac Disease, Covid19, Cardiotoxicity, Extracellular Space Alteration
- Trial name
- NCT04880317
- Testing
- Cardiac Magnetic Resonance, Additional CT acquisition, Blood tests
- Where
- Italy
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- IRCCS Policlinico S. Donato
Locally Advanced Lung Non-Small Cell Carcinoma
Improving the Success Rate for Thoracic Radiotherapy Through Specific Cardiac Substructure Dosimetry: Location Matters. (LOCATION MATTERS)
The prospective study LOCATION MATTERS aims to investigate the radiation-induced damage to the heart and the cardiovascular system in patients treated with thoracic radiotherapy.
- Trial name
- LM (NCT06361784)
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Acute Lung Injury, Prevention
PirfenidoneVsPlacebo as Prophylaxis Against Acute Radiation-induced Lung Injury Following HFRT in Breast Cancer Patients
The incidence of chest CT manifestations of lung injury after radiotherapy for breast cancer is more than 50%. Although the prognosis and quality of life of patients are rarely affected, it is still necessary to prevent the…
- Trial name
- NCT05704166
- Where
- China
- Volunteers
- 214 people
- Sponsor
- Fujian Medical University Union Hospital
Interstitial Lung Disease, Idiopathic Interstitial Pneumonias
FAPI PET for Lung Fibrosis
This is a prospective exploratory biodistribution study in patients with interstitial lung disease (ILD). The purpose of this research study is to determine where and to which degree the FAPI tracer (68Ga-FAPI-46) accumulates in…
- Conditions
- Interstitial Lung Disease, Idiopathic Interstitial Pneumonias, Drug-Induced Pneumonitis, Hypersensitivity Pneumonitis
- Trial name
- FAPI ILD (NCT05365802)
- Testing
- 68Ga-FAPi-46, Computed Tomography, Positron Emission Tomography
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of California, Los Angeles
Non-small Cell Lung Cancer Stage III
Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy
Patients with stage III non-small-cell lung cancer initially evaluated as unresectable are selected for the program, who are remained unresectable after 2-4 cycles of conversion chemotherapy combined with immune checkpoint…
- Trial name
- NCT06031597
- Testing
- radiotherapy, Platinum-Based Drug, Immunotherapy
- Volunteers
- 105 people
- Sponsor
- Zhejiang Cancer Hospital
Non-small Cell Lung Cancer, Radiation Toxicity
Detecting Radiation-Induced Cardiac Toxicity After Non-Small Cell Lung Cancer Radiotherapy
Lung cancer is the most common cause of cancer death in Canada. For approximately 30% of patients that present with locally-advanced non-small cell lung cancer (NSCLC), the standard treatment is curative-intent concurrent…
- Trial name
- RICT-LUNG (NCT03416972)
- Testing
- Standard platinum-based chemoradiotherapy
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Non Small Cell Lung Cancer, Nephropathy
Effect of Genetic and Epigenetic Factors on the Clinical Response and Toxicity to Cisplatin Among Egyptian Non-small Cell Lung Cancer Patients
Lung cancer is the leading cause of death worldwide, with non-small-cell lung cancer (NSCLC) being the most common histotype according to the global cancer observatory 2022.
- Conditions
- Non Small Cell Lung Cancer, Nephropathy, Cardiotoxicity
- Trial name
- NCT05746598
- Testing
- Cisplatin injection
- Where
- Egypt
- Volunteers
- 178 people
- Sponsor
- Ain Shams University
Non-small Cell Lung Cancer, Esophageal Cancer
Radiation-induced Toxicity of the Heart
Late side effects in radio(chemo)therapy [R(CH)T] pose a critical limitation to patients' overall survival and quality of life. Even though toxicities of the heart are highly relevant for patients with cancer in the thoracic…
- Conditions
- Non-small Cell Lung Cancer, Esophageal Cancer, Breast Cancer Female
- Trial name
- CorTox (NCT06986291)
- Testing
- Imaging and biomarkers
- Where
- Germany
- Volunteers
- 325 people
- Sponsor
- Technische Universität Dresden
Drug/Agent Toxicity by Tissue/Organ, Lung Cancer
Amifostine, Chemotherapy, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Conditions
- Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Radiation Toxicity
- Trial name
- NCT00004176
- Testing
- amifostine trihydrate, cisplatin, etoposide
- Where
- 4 sites in United States
- Volunteers
- 34 people
- Sponsor
- Washington University School of Medicine
Lung Cancer, Thoracic Cancer
Investigating Radiation-Induced Injury to Airways and Pulmonary Vasculature in Lung Stereotactic Ablative Body Radiotherapy (SAbR)
We will conduct a prospective clinical study involving up to 40 non-Small Cell Lung Cancer (nSCLC) patients to determine dose thresholds for central and peripheral BSS elements.
- Trial name
- NCT05459311
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Texas Southwestern Medical Center
SBRT, Non-small Cell Lung Cancer
Lung Perfusion PET / CT Using Ga68-MAA for Preservation of Lung Function During Stereotactic Pulmonary Radiation Therapy
This is a prospective study evaluating the feasibility of treatment planning integrating lung perfusion PET/CT using Ga68-MAA to preserve functional lung areas during stereotactic body radiation therapy (SBRT).
- Conditions
- SBRT, Non-small Cell Lung Cancer, Lung Metastasis
- Trial name
- PEGASUS (NCT04942275)
- Testing
- Pre-therapeutic imaging test
- Where
- France
- Volunteers
- 60 people
- Sponsor
- University Hospital, Brest
Radiation Induced Lung Injury (RILI)
Hyperpolarized 129Xe Magnetic Resonance Imaging for Evaluation of Radiation-Induced Lung Injury in Subjects Undergoing Thoracic Irradiation
The purpose of this work is to perform hyperpolarized (HP) 129Xe MRI in human subjects undergoing thoracic radiation therapy (RT), both before, during and following RT.
- Trial name
- RILI (NCT03431129)
- Testing
- Hyperpolarized gas and proton lung MRI
- Where
- Canada
- Volunteers
- 1 people
- Sponsor
- The Hospital for Sick Children
Non-Small Cell Lung Cancer (MeSH Term: Carcinoma, Non-Small-Cell Lung), Drug-Related Side Effects and Adverse Reactions (MeSH Term)
Cancer Therapy-Related Cardiac Dysfunction Associated With EGFR-TKIs in Advanced EGFR-mutant Non-small Cell Lung Cancer
This study investigated the incidence of cardiac dysfunction in patients with advanced or recurrent epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer treated with EGFR- tyrosine kinase inhibitors.
- Conditions
- Non-Small Cell Lung Cancer (MeSH Term: Carcinoma, Non-Small-Cell Lung), Drug-Related Side Effects and Adverse Reactions (MeSH Term), Egfr Tyrosine Kinase Inhibitor, Cardiotoxicity
- Trial name
- NCT07267247
- Testing
- EGFR-TKI, EGFR tyrosine kinase inhibitor
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- Taichung Veterans General Hospital
Thoracic Neoplasms
Prospective Study on Factors Predicting Chemo-Radiotherapy Induced Pulmonary and Esophageal Injury
The purpose of this study is to evaluate clinical, dosimetrical, functional, biological and genetic factors in predicting chemo-radiotherapy induced lung and esophagus injury.
- Trial name
- NCT00631839
- Testing
- Thoracic 3-D Conformal Radiotherapy
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Shanghai Cancer Hospital, China
Drug/Agent Toxicity by Tissue/Organ, Lung Cancer
Amifostine in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer
RATIONALE: Amifostine may be an effective treatment for the toxic side effects caused by radiation therapy and chemotherapy. It is not yet known whether chemotherapy and radiation therapy are more effective with or without…
- Conditions
- Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Oral Complications, Radiation Toxicity
- Trial name
- NCT00003313
- Testing
- filgrastim, amifostine trihydrate, carboplatin
- Where
- 264 sites in United States, Canada
- Volunteers
- 243 people
- Sponsor
- Radiation Therapy Oncology Group
Thoracic Cancer
Bronchial Mapping (GCC 1635)
In order to better understand radiation-induced lung toxicity, the investigator proposes a novel functional avoidance approach that incorporates central as well as peripheral BSS segments in the treatment planning process in…
- Trial name
- NCT02745548
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Maryland, Baltimore
Ototoxicity
SPI-1005 for Prevention and Treatment of Tobramycin Induced Ototoxicity
The primary objective of this study is to determine the safety and efficacy of SPI-1005 treatment in CF patients with active pulmonary exacerbation that are receiving an IV course of tobramycin, determined by comparing hearing…
- Trial name
- NCT02819856
- Testing
- SPI-1005 Ebselen 200mg Capsule x1, SPI-1005 Ebselen 200mg Capsule x2, SPI-1005 Ebselen 200mg Capsule x3
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Sound Pharmaceuticals, Incorporated
Radiation-induced Lung Injury, Immune-related Pneumonia
Pirfenidone Capsules in the Treatment of Radiation-induced Lung Injury With or Without Immune Pneumonia
Radiation-induced lung injury (RILI) is one of the most common thoracic-radiotherapy complications, with an incidence as high as 31.4 %.
- Trial name
- NCT07388680
- Testing
- Pirfenidone Capsules （400 mg）, Pirfenidone Capsules（600mg）, Pirfenidone Capsules（0mg）
- Where
- 36 sites in China
- Volunteers
- 298 people
- Sponsor
- Beijing Continent Pharmaceutical Co, Ltd.
Cardiotoxicity
Effect of Trimetazidine on Radiotherapy-induced Heart Damage.
This is a randomized controlled trial. 80 patients with thoracic radiotherapy will be included. Participants will be randomly divided into experimental group or control group.
- Trial name
- NCT04939857
- Testing
- Trimetazidine
- Volunteers
- 80 people
- Sponsor
- Peking University Third Hospital